COMPANY PROFILE // THE 014 REPORT
aTYR PHARMA INC
ATYR (Nasdaq)
Assembled from 4 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-06-08 and 1 more time (last 24 months).
- AmberLEI 529900ENQUXMC5EBKO36 registration status is LAPSED (last update 2021-07-15): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
aTYR PHARMA INC is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in San Diego, CA; listed as ATYR (Nasdaq).[source] It reported revenue of $190,000 for the fiscal year ended 2025-12-31.[source] It has filed 48 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-13.[source] Its largest institutional holders on 13F filings are FEDERATED HERMES, INC., VANGUARD CAPITAL MANAGEMENT LLC, Kalehua Capital Management LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; LEI 529900ENQUXMC5EBKO36 registration status is LAPSED (last update 2021-07-15).[source]
- red0
- amber2
- info1
- FEDERATED HERMES, INC.$5.1M
- VANGUARD CAPITAL MANAGEMENT LLC$2.3M
- Kalehua Capital Management LLC$2.1M
- AQR CAPITAL MANAGEMENT LLC$1.6M
- FMR LLC$1.5M
- BlackRock, Inc.$1.1M
- JANE STREET GROUP, LLC$1.0M
- UBS Group AG$914K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- Broadfoot Jill Marie · Chief Financial Officer (Officer) · latest Form 4 2026-02-04 · filing · LinkedIn search
- DENYES NANCY · General Counsel (Officer) · latest Form 4 2026-02-04 · filing · LinkedIn search
- Shukla Sanjay · President and CEO (Director,Officer) · latest Form 4 2026-02-04 · filing · LinkedIn search
- BENEVICH ERIC · Director · latest Form 4 2025-05-02 · filing · LinkedIn search
- COUGHLIN TIMOTHY · Director · latest Form 4 2025-05-02 · filing · LinkedIn search
- Gross Jane A · Director · latest Form 4 2025-05-02 · filing · LinkedIn search
- Lucas Svetlana · Director · latest Form 4 2025-05-02 · filing · LinkedIn search
- SCHIMMEL PAUL · Director · latest Form 4 2025-10-09 · filing · LinkedIn search
- Zaknoen Sara · Director · latest Form 4 2025-05-02 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Charles J. Bair . Charles J. Bair Cooley LLP · Exhibit 5.1 legal opinion, S-8 filed 2025-08-07
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001339970 | source |
| LEI | 529900ENQUXMC5EBKO36 | source |
| EIN | 20-3435077 | source |
| California SOS entity | 2007000867 | record |
| Business address (SEC) | 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2019-12-17 · in -2,530 days · LEI next renewal (529900ENQUXMC5EBKO36)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- TALPHERA, INC. · Broadfoot Jill Marie
- Cue Biopharma, Inc. · Broadfoot Jill Marie
- NEUROCRINE BIOSCIENCES INC · BENEVICH ERIC
- Travere Therapeutics, Inc. · COUGHLIN TIMOTHY
- ADC Therapeutics SA · COUGHLIN TIMOTHY
- Jasper Therapeutics, Inc. · Lucas Svetlana
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing 8-K items 8.01 · SEC EDGAR
- 2026-11-06 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-11-06 filing 424B5 · SEC EDGAR
- 2026-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-27 filing 8-K items 5.03,9.01 · SEC EDGAR
- 2026-10-16 filing 8-K items 5.07 · SEC EDGAR
- 2026-09-24 filing 8-K items 8.01 · SEC EDGAR
- 2026-09-11 filing Proxy statement · SEC EDGAR
- 2026-08-31 filing PRE 14A · SEC EDGAR
- 2026-08-07 filing S-8 · SEC EDGAR
- 2026-08-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-31 filing 8-K items 1.02,9.01 · SEC EDGAR
- 2026-06-08 filing 8-K items 3.01 · SEC EDGAR
- 2026-06-01 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-15 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-11 filing 8-K items 2.02,7.01,8.01,9.01 · SEC EDGAR
- 2026-03-26 filing ARS · SEC EDGAR
- 2026-03-26 filing DEFA14A · SEC EDGAR
- 2026-03-26 filing Proxy statement · SEC EDGAR
- 2026-03-12 filing PRE 14A · SEC EDGAR
- 2026-03-05 filing Annual report (10-K) · SEC EDGAR
- 2026-03-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-09 insider First Form 3/4/5 on record for Broadfoot Jill Marie (Chief Financial Officer) · SEC Forms 3/4/5
- 2026-01-09 insider First Form 3/4/5 on record for DENYES NANCY (General Counsel) · SEC Forms 3/4/5
- 2026-01-09 insider First Form 3/4/5 on record for Shukla Sanjay (President and CEO) · SEC Forms 3/4/5
- 2025-12-05 filing 8-K items 3.01 · SEC EDGAR
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
170 earlier entries
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-09-15 filing 8-K items 8.01,9.01
- 2025-08-18 filing EFFECT
- 2025-08-13 filing CORRESP
- 2025-08-13 filing UPLOAD
- 2025-08-08 filing 8-K/A items 2.02,9.01
- 2025-08-07 filing S-8
- 2025-08-07 filing S-3
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.06,9.01
- 2025-05-07 filing Quarterly report (10-Q)
- 2025-05-07 filing 8-K items 2.02,9.01
- 2025-05-06 officer change 8-K items 5.02,5.07,9.01
- 2025-05-02 insider First Form 3/4/5 on record for BENEVICH ERIC (Director)
- 2025-05-02 insider First Form 3/4/5 on record for COUGHLIN TIMOTHY (Director)
- 2025-05-02 insider First Form 3/4/5 on record for Gross Jane A (Director)
- 2025-05-02 insider First Form 3/4/5 on record for Lucas Svetlana (Director)
- 2025-05-02 insider First Form 3/4/5 on record for SCHIMMEL PAUL (Director)
- 2025-05-02 insider First Form 3/4/5 on record for Zaknoen Sara (Director)
- 2025-03-19 filing ARS
- 2025-03-19 filing DEFA14A
- 2025-03-19 filing Proxy statement
- 2025-03-13 filing Annual report (10-K)
- 2025-03-13 filing 8-K items 2.02,9.01
- 2024-12-23 filing 424B5
- 2024-12-23 filing 8-K items 1.01,9.01
- 2024-12-12 officer change 8-K items 5.02,9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-08-13 filing S-8
- 2024-08-13 filing Quarterly report (10-Q)
- 2024-08-13 filing 8-K items 2.02,9.01
- 2024-07-22 filing 8-K items 8.01
- 2024-06-25 filing UPLOAD
- 2024-06-18 filing CORRESP
- 2024-06-06 filing UPLOAD
- 2024-05-29 officer change 8-K items 5.02,5.05,5.07,8.01,9.01
- 2024-05-02 filing Quarterly report (10-Q)
- 2024-05-02 filing 8-K items 2.02,9.01
- 2024-04-05 filing ARS
- 2024-04-05 filing DEFA14A
- 2024-04-05 filing Proxy statement
- 2024-03-14 filing Annual report (10-K)
- 2024-03-14 filing 8-K items 2.02,9.01
- 2023-11-20 filing EFFECT
- 2023-11-16 filing CORRESP
- 2023-11-15 filing UPLOAD
- 2023-11-09 filing S-3
- 2023-11-09 filing 424B5
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-11-09 filing 8-K items 2.02,9.01
- 2023-09-26 filing 8-K items 7.01,8.01,9.01
- 2023-09-11 filing 8-K items 8.01
- 2023-08-10 filing S-8
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-09 filing 8-K items 2.02,9.01
- 2023-05-19 officer change 8-K items 5.02,5.03,5.05,5.07,9.01
- 2023-05-09 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 2.02,9.01
- 2023-04-18 filing ARS
- 2023-03-29 filing DEFA14A
- 2023-03-29 filing DEFA14A
- 2023-03-29 filing Proxy statement
- 2023-03-14 filing Annual report (10-K)
- 2023-03-10 filing 8-K items 7.01
- 2023-03-09 filing 8-K items 2.02,9.01
- 2023-03-08 filing PRE 14A
- 2023-02-09 filing 8-K items 8.01,9.01
- 2023-02-09 filing 424B5
- 2023-02-08 filing 424B5
- 2023-02-06 filing 8-K items 8.01
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-08-15 filing 8-K items 2.02,9.01
- 2022-08-11 filing 8-K items 8.01
- 2022-05-17 filing 8-K items 8.01,9.01
- 2022-05-16 filing 8-K items 1.01,9.01
- 2022-05-11 filing S-8
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-09 filing 8-K items 2.02,9.01
- 2022-04-29 officer change 8-K items 5.02,5.03,5.07,9.01
- 2022-04-22 filing 8-K items 1.01,1.02,9.01
- 2022-04-22 filing 424B5
- 2022-04-14 filing 8-K/A items 8.01
- 2022-04-13 filing 8-K items 2.02,9.01
- 2022-04-08 filing EFFECT
- 2022-04-05 filing CORRESP
- 2022-03-22 filing DEFA14A
- 2022-03-22 filing Proxy statement
- 2022-03-17 filing UPLOAD
- 2022-03-15 filing S-3
- 2022-03-15 filing Annual report (10-K)
- 2022-03-14 filing 8-K items 2.02,9.01
- 2022-03-04 filing PRE 14A
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-11-10 filing 8-K items 9.01
- 2021-09-16 filing 8-K items 8.01,9.01
- 2021-09-16 filing 424B5
- 2021-09-15 filing S-3MEF
- 2021-09-15 filing 424B5
- 2021-09-13 filing 8-K items 8.01,9.01
- 2021-08-23 filing EFFECT
- 2021-08-23 filing UPLOAD
- 2021-08-19 filing CORRESP
- 2021-08-11 filing S-3
- 2021-08-11 filing Quarterly report (10-Q)
- 2021-08-10 filing 8-K items 9.01
- 2021-05-25 filing 8-K items 9.01
- 2021-05-14 filing S-8
- 2021-05-14 filing Quarterly report (10-Q)
- 2021-05-13 filing 8-K items 2.02,9.01
- 2021-05-04 filing 8-K items 8.01,9.01
- 2021-03-24 filing 424B5
- 2021-03-24 filing Annual report (10-K)
- 2021-03-24 filing DEFA14A
- 2021-03-24 filing Proxy statement
- 2021-03-23 filing 8-K items 2.02,9.01
- 2021-03-15 filing 8-K items 8.01,9.01
- 2021-03-09 filing PRE 14A
- 2021-02-09 filing 8-K items 8.01,9.01
- 2021-02-09 filing 424B5
- 2021-01-25 filing 8-K items 7.01,9.01
- 2021-01-22 filing 8-K items 7.01,9.01
- 2021-01-14 filing 8-K items 8.01,9.01
- 2021-01-11 filing 8-K items 7.01,9.01
- 2021-01-04 filing 8-K items 8.01,9.01
- 2020-11-23 filing EFFECT
- 2020-11-19 filing CORRESP
- 2020-11-18 filing UPLOAD
- 2020-11-16 filing S-3
- 2020-11-16 filing 424B5
- 2020-11-13 filing Quarterly report (10-Q)
- 2020-11-12 filing 8-K items 2.02,9.01
- 2020-10-02 filing 424B3
- 2020-09-28 filing EFFECT
- 2020-09-24 filing UPLOAD
- 2020-09-24 filing CORRESP
- 2020-09-18 filing Registration (S-1)
- 2020-09-14 filing 8-K items 1.01,3.02,9.01
- 2020-08-18 filing S-8
- 2020-08-13 filing Quarterly report (10-Q)
- 2020-08-13 filing 8-K items 2.02,9.01
- 2020-06-22 filing 8-K items 7.01,9.01
- 2020-05-20 filing 8-K items 8.01,9.01
- 2020-05-20 filing 424B5
- 2020-05-18 filing 8-K items 7.01,9.01
- 2020-05-12 filing Quarterly report (10-Q)
- 2020-05-12 filing 8-K items 2.02,9.01
- 2020-05-08 officer change 8-K items 5.02,5.07,9.01
- 2020-04-21 filing 8-K items 8.01,9.01
- 2020-04-02 filing Proxy statement
- 2020-03-26 filing Annual report (10-K)
- 2020-03-26 filing 8-K items 2.02,9.01
- 2020-03-18 filing PRE 14A
- 2020-02-28 officer change 8-K items 5.02
- 2020-02-14 filing SC 13D/A
- 2020-02-06 filing 424B4
- 2020-02-06 filing POS EX
- 2020-02-05 filing EFFECT
- 2020-02-05 filing S-1MEF
- 2020-02-03 filing CORRESP
- 2020-02-03 filing CORRESP
- 2020-02-03 filing S-1/A
- 2020-01-27 filing S-1/A
- 2020-01-23 filing UPLOAD
- 2020-01-17 filing Registration (S-1)
- 2020-01-06 filing 8-K items 1.01,9.01
- 2019-12-12 filing 8-K items 8.01,9.01
- 2019-11-14 filing Quarterly report (10-Q)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 8-K filed: Item 8.01 other event
- 2026-11-06 (within 30 days) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-06 (within 30 days) 424B5 filed
- 2026-11-06 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-27 (within 30 days) 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-10-16 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-09-24 (older) 8-K filed: Item 8.01 other event
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:ATYR The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
5 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1339970 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | ATYR / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 529900ENQUXMC5EBKO36 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 529900ENQUXMC5EBKO36) | GLEIF |
| EIN | 203435077 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001339970 | SEC EDGAR / IRS |
| CUSIP | 002120202 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001339970 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110071455004 (ATYR PHARMA INC) | name-exact:legal-name: same registered legal name as 'aTYR PHARMA INC' | EPA ECHO facilities |
| EPA FRS id | 110059750899 (ATYR PHARMA INC) | name-exact:legal-name: same registered legal name as 'aTYR PHARMA INC' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $190,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 05:33 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$74,118,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 05:33 UTC | Report an error |
| Total assets (at 2025-12-31) | $93,003,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 05:33 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $67,480,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 05:33 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $10,743,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 05:33 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
| State of incorporation | DE | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
| Business address | 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 05:33 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$61,986,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 05:33 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $77,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 05:33 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $11,144,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 05:33 UTC | Report an error |
| Form D total offering amount (D filed 2017-09-15) | $45,849,982 | 2017-09-15 | D | as filed | 2026-11-20 05:33 UTC | Report an error |
| Form D total amount sold (D filed 2017-09-15) | $45,849,982 | 2017-09-15 | D | as filed | 2026-11-20 05:33 UTC | Report an error |
| Form D industry group | Biotechnology | 2017-09-15 | D | as filed | 2026-11-20 05:33 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2017-09-15 | D | as filed | 2026-11-20 05:33 UTC | Report an error |
| Form D date of first sale | 2017-08-31 | 2017-09-15 | D | as filed | 2026-11-20 05:33 UTC | Report an error |
| Plan (pension, plan no. 001) | ATYR PHARMA, INC. 401(K) PLAN: 85 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-20 05:33 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-06 · accession 0001339970-26-000081
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-06 | 0001339970-26-000081 | 2026-11-20 05:33 UTC | Report an error |
| Net income (loss) | -$18,261,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-06 | 0001339970-26-000081 | 2026-11-20 05:33 UTC | Report an error |
| Cash and cash equivalents | $13,140,000 | at 2026-09-30 | 10-Q | 2026-11-06 | 0001339970-26-000081 | 2026-11-20 05:33 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 8-K filed: Item 8.01 other event
- 2026-11-06 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-06 Filing 424B5 filed
- 2026-11-06 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-27 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-10-16 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-09-24 Filing 8-K filed: Item 8.01 other event
- 2026-09-11 Filing DEF 14A filed
- 2026-08-31 Filing PRE 14A filed
- 2026-08-07 Filing S-8 filed
- 2026-08-07 Filing 10-Q filed
- 2026-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-31 Filing 8-K filed: Item 1.02 agreement terminated; Item 9.01 exhibits
- 2026-06-08 Filing 8-K filed: Item 3.01 delisting notice
- 2026-06-01 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-22 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-05-15 Filing 10-Q filed
- 2026-05-15 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-11 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-26 Filing ARS filed
- 2026-03-26 Filing DEFA14A filed
- 2026-03-26 Filing DEF 14A filed
- 2026-03-12 Filing PRE 14A filed
- 2026-03-05 Filing 10-K filed
2 earlier entries
- 2026-03-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2008-01-01 Record plan effective date: ATYR PHARMA, INC. 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set… the 8-K · retrieved 2026-11-20 05:33 UTC - 2026-10-27 8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On October 27, 2026, aTyr Pharma, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split (the “Reverse Stock Split”) of its outstanding common stock. The Amendment will be effective at 5:00 p.m. Eastern Time on October 28, 2026. A series of alternate amendments to effect a reverse stock split was approved by the Company’s stockholders at the Company’s Special Meeting of Stockholders held on October 16, 2026, and the specific one-for-forty (1-for-40) Reverse Stock Split was subsequently approved by the… the 8-K · retrieved 2026-11-20 05:33 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchATYR PHARMA INC · exact legal name · sx:epa:110071455004 Compare
- possible matchATYR PHARMA INC · exact legal name · sx:epa:110059750899 Compare
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchATYR PHARMA INC · exact legal name · sx:rcra:CAL000373279 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | $5,078,576 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $2,273,430 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 3 | Kalehua Capital Management LLC | $2,134,356 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 4 | AQR CAPITAL MANAGEMENT LLC | $1,557,975 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 5 | FMR LLC | $1,474,942 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 6 | BlackRock, Inc. | $1,090,552 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 7 | JANE STREET GROUP, LLC | $1,027,270 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 8 | UBS Group AG | $914,097 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 9 | TWO SIGMA INVESTMENTS, LP | $743,104 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
| 10 | CITADEL ADVISORS LLC | $741,265 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:33 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Atyr Pharma, Inc. · LEI 529900ENQUXMC5EBKO36 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchATYR PHARMA INC · exact legal name · sx:cabiz:sd:2007000867 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchaTyr Pharma, Inc. · exact legal name · sx:ctgov:h9aa507399005f4df Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1339970.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001339970. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.